OBI Pharma’s Obrion® ADC Technology Platform Wins Product Innovation of the Year at the 2026 Taiwan BIO Awards
2026.Apr.24
News
OBI Announces US FDA Registration and Activation of HYProtecan™ Type II Drug Master File
Supporting Obrion Engine™ ADC Technologies and Enhancing Regulatory Efficiency
2026.Mar.03
News
OBI Receives Acceptance of Ten Abstracts at 2026 AACR
Advances Next-Generation ADC Development and Global Partnerships
2025.Dec.19
News
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC
2025.Dec.18
News
OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation
2025.Dec.05
News
OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma
2025.Nov.16
News
OBI-902 has been granted by US FDA for Orphan Drug Designation for the treatment of Cholangiocarcinoma.
2025.Sep.26
News
OBI Invited to Present ADC Technology Platform and Chaired Sessions at Biologics World Korea 2025
2025.Sep.03
News
OBI Pharma and AP Biosciences Sign Technology Collaboration Agreement to Develop Next-Generation ADC
2025.Aug.31
News
OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors
2025.Jun.06
News
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
Events
Scientific
BIO ASIA-TAIWAN 2026
2026.Jul.16 ~ 2026.Jul.19
Taipei Nangang Exhibition Center, Hall 1 (TaiNEX1)
Event Time2026.Jul.16 ~ 2026.Jul.19
Event LocationTaipei Nangang Exhibition Center, Hall 1 (TaiNEX1)
